Woodline Partners is a hedge fund that employs a market-neutral, long/short equity strategy, focusing on generating "idiosyncratic alpha" through bottom-up fundamental research. They primarily invest in the healthcare, technology, and industrial sectors, utilizing shorts to hedge market risk.
Portfolio
7
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Stage Distribution
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Blue Earth Therapeutics Ltd | Series A | $76.5M | Oct 2024 |
| Build A Rocket Boy | Series D | $110M | Jan 2024 |
| Odyssey Therapeutics, Inc. | Series A | $218M | Dec 2021 |
| Arbor Biotechnologies Inc | Series B | $215M | Nov 2021 |
| SmartNews | Series F | $230M | Sep 2021 |
| Affinia Therapeutics | Series B | $110M | May 2021 |
| Patreon | Growth | $155M | Apr 2021 |
Top Co-Investors
NEA (New Enterprise Associates)2 shared
Logos Capital2 shared
Princeville Capital1 shared
JIC Venture Growth Investments1 shared
ACA Investments1 shared
RedBird Capital1 shared
Endeavor1 shared
Alignment Growth1 shared
Tiger Global Management1 shared
Wellington Management1 shared
Lone Pine Capital1 shared
Glade Brook Capital Partners1 shared
DFJ Growth1 shared
Farallon Capital Management1 shared
Avidity Partners1 shared
Casdin Capital1 shared
GV (Google Ventures)1 shared
Perceptive Advisors1 shared
RA Capital Management1 shared
Atlas Venture1 shared
Last updated: 3 March 2026